A study published in August 2025 indicates a link between papillary thyroid cancer (PTC) and obesity, though the precise biological mechanisms driving this connection remain incompletely understood. Researchers investigating the role of the immune system in PTC patients, stratified by Body Mass Index (BMI), found immune microenvironment differences were not strongly influenced by BMI.
The research, detailed in PubMed, analyzed gene expression profiles of over 700 immune-related genes in 36 PTC samples. Patients were categorized into four groups: underweight, normal weight, overweight, and obese. The normal weight group served as a baseline for comparison. Analysis revealed that the immune profiles of underweight and obese patients exhibited similar dysregulation in pathways related to T-cell differentiation, macrophage activation, cell cycle regulation, and senescence.
Specifically, the study identified significant downregulation of HMGB1 in both the underweight and obese groups, coupled with upregulation of ARG2 in the obese group. Researchers suggest these genes may offer insights into the immunometabolism of thyroid cancer, though further investigation is necessary. The study did not locate a strong influence of BMI on the overall immune microenvironment of PTCs.
A separate study from December 2020, published in the Surgery Research Journal, aimed to investigate the clinical and pathological relevance between BMI and PTC. A retrospective analysis was conducted, but specific findings were not detailed in the available summary.
Recent research published by MDPI in July 2023 indicated that higher BMI showed no evidence of association with papillary thyroid carcinoma. This contrasts with earlier findings suggesting a link between obesity and the disease.
A retrospective study published in ScienceDirect in 2022 focused on the association of BMI with clinicopathological features of PTC. The study’s findings were not detailed in the available summary.
